Asusi, Gwendoline .
HRN: 26-26-72 Sex: FemalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
12/01/2024
METRONIDAZOLE 5MG/ML, 100ML (VIAL)
12/01/2024
12/07/2024
IV
500 Mg
Q8
HAP Tc Endometritis
Waiting Final Action
Indication: Empiric Type of Infection: Intra-abdominal Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes